RxDoctor Payments DataLook up a doctor →

Akinyemi Ajayi, MD

Pediatric Pulmonology · Winter Park, FLNPI 1215915152

Payments from drug & device makers

$1,983,800in general payments, 2019–2025

Across 869 payments — averaging $2282.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$745K
  • Jazz Pharmaceuticals Inc.$741K
  • Idorsia Pharmaceuticals US Inc$221K
  • Avadel CNS Pharmaceuticals, LLC$68K
  • Teva Pharmaceuticals USA, Inc.$67K
  • Novartis$44K
  • plus $98K from 24 others
$11,052in research payments, 2019–2025

Across 6 payments — averaging $1842.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Arbor Pharmaceuticals, Inc.$9K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K

What the payments were for

  • Consulting fees$75,63817%
  • Speaking & faculty fees$289,81867%
  • Travel & lodging$53,42312%
  • Food & beverage$14,5113%
  • Education$940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,983,800 in reported general payments places this provider in the 95th percentile of 72 pediatric pulmonology providers in Florida.

See all pediatric pulmonology providers in Florida

Medicare billing

Part B allowed, 2024
$1,652
Medicare patients
13
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Modafinil23$9,025
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine25$1,183

Paid to pharmacies, not to this prescriber.

Other pediatric pulmonology in Winter Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →